HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

AbstractBACKGROUND:
Neuraminidase (NA) inhibitors (NAIs) are currently the only antivirals effective against influenza infections due to widespread resistance to M2 inhibitors.
METHODS:
Influenza A and B viruses (n = 1079) collected worldwide between April 01, 2011, and September 30, 2011, were assessed for susceptibility to FDA-approved NAIs, oseltamivir and zanamivir, and investigational peramivir, using the fluorescent-based NA-Fluor™ Influenza Neuraminidase Assay Kit. A subset of viruses (n = 98) were tested for susceptibility to the investigational NAI, laninamivir.
RESULTS:
Influenza A(H1N1)pdm09 viruses (n = 326) were sensitive to all NAIs, except for two (0.6%) with H275Y (N1 numbering; H274Y in N2 numbering) substitution, which exhibited elevated IC50 s for oseltamivir and peramivir, and a third with previously unreported N325K substitution, exhibiting reduced susceptibility to oseltamivir. Influenza A(H3N2) viruses (n = 407) were sensitive to all NAIs. Influenza B viruses (n = 346) were sensitive to all NAIs, except two (0.6%) with H273Y (N1 numbering; H274Y in N2 numbering) substitution, exhibiting reduced susceptibility to oseltamivir and peramivir, and one with previously unreported G140R and N144K substitutions, exhibiting reduced susceptibility to oseltamivir, zanamivir, and peramivir. All influenza A and B viruses were sensitive to laninamivir. It is unknown whether substitutions N325K, G140R, and N144K were present in the virus prior to culturing because clinical specimens were unavailable for testing.
CONCLUSIONS:
This study summarizes NAI susceptibility of influenza viruses circulating worldwide during the 2011 Southern Hemisphere (SH) season, assessed using the NA-Fluor™ Kit. Despite low resistance to NAIs among tested influenza viruses, constant surveillance of influenza virus susceptibility to NAIs should be emphasized.
AuthorsMargaret Okomo-Adhiambo, Katrina Sleeman, Colleen Lysén, Ha T Nguyen, Xiyan Xu, Yan Li, Alexander I Klimov, Larisa V Gubareva
JournalInfluenza and other respiratory viruses (Influenza Other Respir Viruses) Vol. 7 Issue 5 Pg. 645-58 (Sep 2013) ISSN: 1750-2659 [Electronic] England
PMID23575174 (Publication Type: Journal Article)
Copyright© 2013 John Wiley & Sons Ltd.
Chemical References
  • Acids, Carbocyclic
  • Antiviral Agents
  • Cyclopentanes
  • Enzyme Inhibitors
  • Guanidines
  • Pyrans
  • Sialic Acids
  • Oseltamivir
  • laninamivir
  • Neuraminidase
  • Zanamivir
  • peramivir
Topics
  • Acids, Carbocyclic
  • Africa
  • Antiviral Agents (pharmacology)
  • Cyclopentanes (pharmacology)
  • Drug Resistance, Viral
  • Enzyme Inhibitors (pharmacology)
  • Global Health
  • Guanidines (pharmacology)
  • Humans
  • Influenza A Virus, H1N1 Subtype (drug effects, genetics, isolation & purification)
  • Influenza A Virus, H3N2 Subtype (drug effects, genetics, isolation & purification)
  • Influenza B virus (drug effects, genetics, isolation & purification)
  • Influenza, Human (drug therapy, virology)
  • Neuraminidase (antagonists & inhibitors)
  • Oceania
  • Oseltamivir (pharmacology)
  • Pyrans
  • Seasons
  • Sentinel Surveillance
  • Sialic Acids
  • South America
  • Zanamivir (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: